HomeCompareELYM vs KMB

ELYM vs KMB: Dividend Comparison 2026

ELYM yields 39.14% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELYM wins by $175.3K in total portfolio value
10 years
ELYM
ELYM
● Live price
39.14%
Share price
$5.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$221.2K
Annual income
$36,710.06
Full ELYM calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.35
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,222.34
Full KMB calculator →

Portfolio growth — ELYM vs KMB

📍 ELYM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELYMKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELYM + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELYM pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELYM
Annual income on $10K today (after 15% tax)
$3,326.81/yr
After 10yr DRIP, annual income (after tax)
$31,203.55/yr
KMB
Annual income on $10K today (after 15% tax)
$446.39/yr
After 10yr DRIP, annual income (after tax)
$4,438.99/yr
At 15% tax rate, ELYM beats the other by $26,764.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELYM + KMB for your $10,000?

ELYM: 50%KMB: 50%
100% KMB50/50100% ELYM
Portfolio after 10yr
$133.6K
Annual income
$20,966.20/yr
Blended yield
15.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

ELYM
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Altman Z
25.2
Piotroski
2/9
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.7% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELYM buys
0
KMB buys
0
No recent congressional trades found for ELYM or KMB in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELYMKMB
Forward yield39.14%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$221.2K$45.9K
Annual income after 10y$36,710.06$5,222.34
Total dividends collected$165.4K$21.6K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: ELYM vs KMB ($10,000, DRIP)

YearELYM PortfolioELYM Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$14,614$3,913.89$11,314$614.45+$3.3KELYM
2$20,982$5,345.54$12,867$760.19+$8.1KELYM
3$29,624$7,172.93$14,713$945.27+$14.9KELYM
4$41,162$9,464.62$16,924$1,181.90+$24.2KELYM
5$56,334$12,290.65$19,596$1,486.64+$36.7KELYM
6$75,998$15,720.42$22,850$1,882.16+$53.1KELYM
7$101,138$19,820.29$26,849$2,399.80+$74.3KELYM
8$132,869$24,651.24$31,812$3,083.36+$101.1KELYM
9$172,437$30,266.60$38,033$3,994.72+$134.4KELYM
10$221,217$36,710.06$45,918$5,222.34+$175.3KELYM

ELYM vs KMB: Complete Analysis 2026

ELYMStock

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.

Full ELYM Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this ELYM vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELYM vs SCHDELYM vs JEPIELYM vs OELYM vs KOELYM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.